AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25331625
Drug: ACT-246475 (dF)
RxNorm normalized name: ACT-246475
DrugBank: Selatogrel (DB15163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-246475 (dF) 50 mg
Trial: 25331625
Drug: ACT-281959 (F1)
RxNorm normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACT-281959 (F1) 70 mg
Trial: 23526240
Drug: Diclofenac +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac + B vitamins mixture (75 mg sodium diclofenac, 100 mg thiamine, 100 mg pyridoxine, 5 mg cyanocobalamin)
Trial: 23526240
Drug: Diclofenac alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac alone (75 mg sodium diclofenac)
Trial: 15247556
Drug: Lopinavir/ritonavir 400/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir 400/100 mg BID + Phenytoin 300 mg QD (days 11-22)
Trial: 15247556
Drug: Phenytoin 300
RxNorm normalized name: phenytoin 300 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin 300 mg QD + Lopinavir/ritonavir 400/100 mg BID (days 12-23)
Trial: 11243418
Drug: Almotriptan 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almotriptan 50 mg
Trial: 8988349
Drug: Morning administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning administration of intranasal salmon calcitonin (sCT) 200 IE
Trial: 8988349
Drug: Evening administration
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening administration of intranasal salmon calcitonin (sCT) 200 IE
Trial: 8500919
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of loxapine
Trial: 8500919
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of loxapine
Trial: 29423947
Drug: AXP1275 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXP1275 (50 mg)
Trial: 12814414
Drug: Short-term pre-operative
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term pre-operative cessation of smoking, counselling and nicotine replacement therapy
Trial: 12814414
Drug: Maintenance of
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance of daily smoking habits
Trial: 10403266
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg twice a day)
Trial: 7587218
Drug: Estrogen and
RxNorm normalized name: Conjugated estrogen and norgestrel only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen and estrogen/progestin therapy
Trial: 30994410
Drug: Telehealth-based health
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth-based health coaching (INT group) with weekly videoconferencing for health coaching and monthly medical monitoring.
Trial: 30994410
Drug: Self-guided (CON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-guided (CON group) without weekly health coaching.
Trial: 30082170
Drug: Apatinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (500 mg once daily) combined with oral etoposide (50 mg once daily on days 1-14 of a 21-day cycle)
Trial: 30082170
Drug: Apatinib combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib combined with oral etoposide
Trial: 20838215
Drug: Trazodone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (100 mg/d before bedtime)
Trial: 27950535
Drug: Erlotinib (E)
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib (E) 150 mg orally QD plus sulindac (S) 150 mg orally BID (Arm A)
Trial: 27950535
Drug: Erlotinib (E)
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib (E) 150 mg QD (Arm B)
Trial: 27950535
Drug: Adjuvant Erlotinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant Erlotinib (E) 150 mg QD for 2 years after postoperative chemoradiotherapy
Trial: 16368840
Drug: Dexamethasone group
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone group (lidocaine 1.5% with 2 mL of dexamethasone 8 mg)
Trial: 16368840
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (lidocaine 1.5% with 2 mL of isotonic saline chloride)
Trial: 14551182
Drug: Nefazodone titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone titrated to a daily dose of 400 mg
Trial: 14551182
Drug: Fluoxetine 60
RxNorm normalized name: fluoxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 60 mg per day for 5 days, followed by 20 mg per day for 7 days
Trial: 14551182
Drug: Fluvoxamine titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine titrated to a daily dose of 200 mg
Trial: 26263075
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg (group O4)
Trial: 26263075
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg (group O8)
Trial: 26263075
Drug: Ramosetron 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 0.3 mg (group R)
Trial: 18822983
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Amantadine tablets for 5 days
Trial: 15702134
Drug: High-dose finasteride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose finasteride
Trial: 10404019
Drug: MK-677 10
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-677 10 mg for 2 weeks
Trial: 10404019
Drug: MK-677 25
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-677 25 mg for 2 weeks
Trial: 10404019
Drug: MK-677 25
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-677 25 mg daily for 2 weeks followed by 50 mg daily for 2 weeks
Trial: 8567514
Drug: CHO+MCT trial
RxNorm normalized name: MCT
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO+MCT trial (15% CHO solution + 29 g MCT suspension)
Trial: 8567514
Drug: HCHO+MCT trial
RxNorm normalized name: MCT
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCHO+MCT trial (high CHO (HCHO) 214 g + 29 g MCT suspension)
Trial: 8567514
Drug: MCT trial
RxNorm normalized name: MCT
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT trial (29 g MCT solution)
Trial: 25062747
Drug: internet-based cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-based cognitive-behavioural therapy (iCBT)
Trial: 20120778
Drug: Enalapril (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (40 mg/day)
Trial: 20120778
Drug: Losartan (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (200 mg/day)
Trial: 16357312
Drug: Rosiglitazone 8
RxNorm normalized name: rosiglitazone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 8 mg daily
Trial: 15215284
Drug: Monthly weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly weight fluctuations
Trial: 11215231
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine 2 ml added to 1% propofol 20 ml (Group L)
Trial: 11215231
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 2 ml added to 1% propofol 20 ml (Group S)
Trial: 8157036
Drug: Fluvastatin 20
RxNorm normalized name: fluvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 20 mg b.d. for 12 weeks and fluvastatin 20 mg AM + 40 mg PM for an additional 12 weeks (Group A)
Trial: 8157036
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg qPM during the entire study (Group B)
Trial: 8157036
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of Group A (60 mg) vs Group B (40 mg qPM)
Trial: 28264693
Drug: Tailored programme
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored programme for implementing recommendations for multimorbid patients with polypharmacy; includes structured medication counselling, medication lists, and medication reviews.
Trial: 18039681
Drug: Step-down treatment
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step-down treatment (COBRA regimen: sulphasalazine 2 g daily, methotrexate 15 mg weekly, oral prednisolone starting at 60 mg daily, tapering to 7.5 mg over 6 weeks)
Trial: 18039681
Drug: Step-up treatment
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step-up treatment (DMARD monotherapy)
Trial: 16413428
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg ddAVP
Trial: 16413428
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg ddAVP
Trial: 9328363
Drug: Low-dose rHuEPO
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rHuEPO (1,500 U intravenously three times a week for 26 weeks)
Trial: 9328363
Drug: Low-dose rHuEPO
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rHuEPO plus nandrolone decanoate (100 mg intramuscularly weekly)
Trial: 8405026
Drug: Pinacidil 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinacidil 0.1 mg/kg IV
Trial: 3533372
Drug: Piretanide (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide (24 mg daily for 28 days)
Trial: 31444820
Drug: S1 implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S1 implants
Trial: 31444820
Drug: S2 implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S2 implants
Trial: 23965696
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 0.25% bupivacaine (nerve block of the infrapatellar branch of the saphenous nerve)
Trial: 14708961
Drug: Combination with
RxNorm normalized name: Iron in combination with folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination with other drugs (cefepime, glycopeptide, linezolid)
Trial: 19563201
Drug: Method with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Method with standard treatment lines
Trial: 17805064
Drug: Irinotecan, carboplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan, carboplatin, and imatinib (600 mg/day); treatment cycles were 28 days.
Trial: 9507618
Drug: Physiotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy treatment regimen
Trial: 8589024
Drug: 5-fluorouracil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil at 300 mg/m2 and folinic acid at 200 mg/m2 daily for five days
Trial: 31823525
Drug: Tropifexor (LJN452)
RxNorm normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropifexor (LJN452) 300 µg with high-fat meal
Trial: 31075314
Drug: Moderate-intensity aerobic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-intensity aerobic training (6 months, thrice weekly)
Trial: 27790726
Drug: GP2015 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP2015 (50 mg s.c. injection)
Trial: 27790726
Drug: GP2015 via
RxNorm normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP2015 via autoinjector (AI) (50 mg s.c. injection)
Trial: 27790726
Drug: ETN (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETN (50 mg s.c. injection)
Trial: 27790726
Drug: GP2015 via
RxNorm normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP2015 via prefilled syringes (PFS) (50 mg s.c. injection)
Trial: 26448615
Drug: Adjunctive aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjunctive aripiprazole treatment (10 mg/day)
Trial: 21828950
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg) in BOS (+) group (n = 4)
Trial: 21828950
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg) in BOS (−) group (n = 4)
Trial: 19854375
Drug: Krill oil
RxNorm normalized name: Krill oil
DrugBank: Krill oil (DB16615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krill oil (2 g/d)
Trial: 19854375
Drug: Menhaden oil
RxNorm normalized name: MENHADEN OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menhaden oil (2 g/d)
Trial: 15566659
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg pamidronate (group A)
Trial: 15566659
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg pamidronate (group B)
Trial: 9217246
Drug: Virend (15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virend (15% ointment)
Trial: 2906474
Drug: Olsalazine (0.75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olsalazine (0.75, 1.5, or 3 g daily)
Trial: 2906474
Drug: Olsalazine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olsalazine (1.5 g and 3 g daily)
Trial: 19789443
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (hemoglobin <70 g/L)
Trial: 19789443
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (hemoglobin <95 g/L)
Trial: 18609051
Drug: Liberal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal fluid prescription (30-35 ml/kg body weight/day)
Trial: 18609051
Drug: Restrictive fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive fluid prescription (maximum fluid intake of 1.5 L/day)
Trial: 8987919
Drug: Vaginal approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal approach with bilateral sacrospinous vault suspension and paravaginal repair
Trial: 8987919
Drug: Abdominal approach
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal approach with colposacral suspension and paravaginal repair
Trial: 1455374
Drug: Pulse therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse therapy with methylprednisolone 25‐30 mg/kg/day for 3 consecutive days combined with cyclophosphamide 0.4‐0.5 g/sq. m BSA on the 3rd day, repeated quarterly for 12 months (Group 1 and Group 2)
Trial: 1455374
Drug: No pulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pulse therapy (Group 3)
Trial: 25269124
Drug: Cognitive processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive processing therapy (n = 32)
Trial: 25269124
Drug: Present centered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Present centered therapy (n = 13)
Trial: 22020317
Drug: S-1 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 administered under fed conditions
Trial: 22020317
Drug: S-1 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 administered under fasting conditions
Trial: 19710195
Drug: Milk group
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk group (3-5 portions of dairy products daily)
Trial: 17261227
Drug: Walnut-supplemented diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut-supplemented diet (≥ 28 g of walnuts per day)
Trial: 17261227
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (≥ 2 g of walnuts per day)
Trial: 15330755
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (1 g of L‐ascorbate, 400 IU of D,L‐alpha‐tocopherol acetate, 600 mg of alpha‐lipoic acid)
Trial: 9554641
Drug: High-frequency oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency oral airway oscillation (frequency 8 Hz; I:E ratio 9:1)
Trial: 9554641
Drug: High-frequency oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency oral airway oscillation (frequency 14 Hz; I:E ratio 8:1)
Trial: 9554641
Drug: Conventional chest
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional chest physical therapy (CPT)
Trial: 24897743
Drug: Physical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Therapy (PT group) - six sessions of a standardized hospital-based physical therapy program
Trial: 24897743
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (no-PT group)
Trial: 24897743
Drug: Physical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Therapy (PT group)
Trial: 20722677
Drug: Tramadol (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (37.5 mg)/Acetaminophen (325 mg)
Trial: 20722677
Drug: Tramadol/Acetaminophen
RxNorm normalized name: TRAMADOL/ACETAMINOPHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol/Acetaminophen
Trial: 19041063
Drug: ATO 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATO 0.15 mg/kg i.v. x 7 days + melphalan 200 mg/m2 i.v. over 2 days + AA 1000 mg i.v. over 7 days
Trial: 19041063
Drug: ATO 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATO 0.25 mg/kg i.v. x 7 days + melphalan 200 mg/m2 i.v. over 2 days + AA 1000 mg i.v. over 7 days
Trial: 19041063
Drug: No ATO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ATO + melphalan 200 mg/m2 i.v. over 2 days + AA 1000 mg i.v. over 7 days
Trial: 19041063
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment arms (ATO + AA + melphalan)
Trial: 8824689
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg nefazodone once daily in the morning (treatment 1)
Trial: 8824689
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg nefazodone once daily in the evening (treatment 2)
Trial: 8824689
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg nefazodone twice daily (treatment 3)
Trial: 1454350
Drug: Augmentation laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation laser panretinal photocoagulation (MORE)
Trial: 1454350
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment (NOMORE)
Trial: 3966664
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with bupivacaine 0.25 mg X kg‐1
Trial: 3966664
Drug: Bupivacaine 0.25
RxNorm normalized name: levobupivacaine 0.25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25 mg X kg‐1 im without surgery (volunteers)
Trial: 24662322
Drug: Anti-CGRP monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CGRP monoclonal antibody (up to 2000 mg)
Trial: 20712261
Drug: levobupivacaine-hyaluronidase 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levobupivacaine-hyaluronidase 10 IU x ml(‐1)
Trial: 20712261
Drug: racemic bupivacaine-hyaluronidase
RxNorm normalized name: Racemic bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: racemic bupivacaine-hyaluronidase 10 IU x ml(‐1)
Trial: 10975012
Drug: Ofloxacin (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (total 15 mg/kg, 2 doses)
Trial: 10975012
Drug: Nalidixic acid
RxNorm normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nalidixic acid (NA: 55 mg/kg daily for 5 days)
Trial: 1574933
Drug: Whole-body cold
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body cold therapy
Trial: 1574933
Drug: Hot mud-pack
RxNorm normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hot mud-pack therapy
Trial: 3882071
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of contrast material (60 to 350 mL)